Asimov

Asimov is developing a synthetic biology platform – from cells to software – to enable better design and manufacture of next-generation therapeutics. Asimov’s CHO Edge System for biologic production minimizes the risk of cell line development by enabling exploration of vector design space, routinely achieving titers of 8–12 g/L across modalities.

Asimov is applying the same approach to improve cell & gene therapies – by developing stable lentiviral cell lines and a best-in-class AAV expression system, and enhancing safety profiles through the creation of synthetic tissue specific promoters.